We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Smoking Cessation Trials Targeted to Racial and Economic Minority Groups

Neal L. Benowitz, MD
JAMA. 2002;288(4):497-499. doi:10.1001/jama.288.4.497.
Text Size: A A A
Published online


Well-documented racial differences in drug response13 have led to considerable debate about "racial profiling" of pharmacotherapy.4,5 Still, it is argued that race is a biologically meaningless term,4 and an understanding of physiology and the genetic underpinnings of drug response is a better way to target therapy. Furthermore, an individualized approach to pharmacotherapy with monitoring of patient response and modification of therapy as necessary might be just as effective as race-guided therapy. Whether to consider race in drug therapy has important implications for physicians, drug developers, and regulators. In this issue of THE JOURNAL, Ahluwalia and colleagues6 present the results of a clinical trial of sustained-release bupropion hydrochloride (bupropion SR) to aid smoking cessation in African American smokers treated at an inner-city community health center. The study demonstrates efficacy of bupropion, but the study design and resultant data raise questions about the ultimate value of pharmacotherapy trials in racial and economic subgroups.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

23 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Emergency Care. Issue Brief Health Policy Track Serv 2015;():1-39.